B+
Bull case
25%
Probability
Target price
$4.30
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
KRMD
KORU MedicalCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$3.35
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$2.15
Analysis reference price unavailable
Analysis 2026-09-29 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-29
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+63.2
Score
AI commentary
Company-reported Q2 growth and profitability are constructive, offset by international moderation and the oncology reset [#SEC-8K-2026-08-05]. The September open-market insider purchase is a limited alignment signal, not evidence of operating performance [#SEC-FORM4-2026-09-09]. The packet does not establish a post-release price reaction, analyst revisions, or sufficient social, options, short-interest or employee data; zero-valued sentiment fields denote unavailable inputs, not neutral readings.
RankAlpha Sentiment Codex - 2026-09-29
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystDelivery against refined 2026 guidanceHigh impact
Q2 revenue rose 18.2% year over year to $12.0 million and gross margin reached 65.1%. The key test is whether KORU delivers its refined 2026 targets: $47.5–$48.5 million revenue, 62%–64% gross margin, positive adjusted EBITDA and year-end cash above $7.5 million. December 31 is an assessment horizon, not an announced results date [#SEC-8K-2026-08-05].
2026-12-31catalystInternational growth moderation and oncology resetHigh impact
Management expects international core growth to moderate during European pre-filled-syringe conversions. KORU also withdrew its FreedomEDGE with Phesgo 510(k) application and redirected its U.S. oncology strategy toward higher-volume molecules; timing and commercial success remain uncertain [#SEC-8K-2026-08-05].
2027-12-31catalystConnected-monitoring commercializationHigh impact
KORU acquired a connected-monitoring technology asset that could differentiate its infusion platform, but the cited release does not establish a launch date, adoption level or financial contribution. The 2027 date is an assessment horizon, not company guidance [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-29 • Updated nightlySource: Internal modelMethodology